FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220783418> ?p ?o ?g. }

• W4220783418 endingPage "529" @default.
• W4220783418 startingPage "529" @default.
• W4220783418 abstract "Patients with hypertrophic obstructive cardiomyopathy (HOCM) and drug-refractory symptoms and outflow gradients have limited nonsurgical treatment options. The feasibility of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported previously; however, procedural and medium-term outcomes are unknown.To describe the safety and medium-term outcomes of PIMSRA in a large patient cohort with drug-refractory HOCM.This was a single-arm, open-label study of PIMSRA in patients with drug-refractory HOCM. Patients presenting to the Xijing Hospital in Xi'an, China, between October 2016 to June 2020 with hypertrophic cardiomyopathy. Of 1314 patients presenting with HOCM, 244 fulfilled inclusion criteria of severe resting/provoked outflow gradients of 50 mm Hg or higher, and symptoms of New York Heart Association functional class of II or higher refractory to maximum tolerated medications. After discussion among the heart team, 40 patients underwent surgical or alcohol septal reduction therapy and 4 required treatment of significant coronary artery disease.PIMSRA performed in patients.The primary outcome was 30-day major adverse clinical events: death, emergency surgery, severe effusion requiring intervention, procedure-related stroke, bleeding, and stroke. Secondary outcomes included 30-day technical success and 90-day improvement in outflow obstruction.The mean (SD) age of 200 patients was 46.9 (14.0) years, and 125 (62.5%) were men. Resting or provoked left ventricular outflow tract gradients were 50 mm Hg or higher. The median (IQR) follow-up for all patients was 19 (6-50) months. Thirty-day major adverse clinical events rate was 10.5% (n = 21): there were 2 in-hospital/30-day deaths (1.0%), 7 patients (3.5%) with pericardial effusion requiring mini-thoracotomy, 12 patients (6%) with pericardial effusion requiring pericardiocentesis, and no bleeding or strokes. Other periprocedural complications included permanent right bundle branch block in 5 patients (2.5%), resuscitated ventricular fibrillation in 2 (1.0%), and septal branch aneurysm in 2 (1.0%). There were no permanent pacemaker implantations. At follow-up, maximum septal thickness was reduced from a mean (SD) of 24.0 (5.1) mm to 17.3 (4.4) mm (P < .001), and left ventricular outflow tract gradient was decreased from a mean (SD) of 79.0 (53.0) mm Hg to 14.0 (24.0) mm Hg (P < .001). Overall, 190 patients (96%) with HOCM were in New York Heart Association functional class I or II at last follow-up.This study found that PIMSRA in patients with drug-refractory HOCM may be an effective procedure for relief of left ventricular outflow tract obstruction and symptoms with acceptable complication rates. These results are encouraging and support the design of a randomized clinical trial against well-established septal reduction therapies." @default.
• W4220783418 created "2022-04-03" @default.
• W4220783418 creator A5004676848 @default.
• W4220783418 creator A5008894558 @default.
• W4220783418 creator A5012618486 @default.
• W4220783418 creator A5012677271 @default.
• W4220783418 creator A5037677450 @default.
• W4220783418 creator A5038860730 @default.
• W4220783418 creator A5039494205 @default.
• W4220783418 creator A5041084808 @default.
• W4220783418 creator A5048283490 @default.
• W4220783418 creator A5050549187 @default.
• W4220783418 creator A5055613208 @default.
• W4220783418 creator A5064940993 @default.
• W4220783418 creator A5066469597 @default.
• W4220783418 creator A5067001113 @default.
• W4220783418 creator A5068745615 @default.
• W4220783418 creator A5071672663 @default.
• W4220783418 creator A5071798264 @default.
• W4220783418 creator A5077679832 @default.
• W4220783418 creator A5082764262 @default.
• W4220783418 creator A5083045371 @default.
• W4220783418 creator A5083665930 @default.
• W4220783418 date "2022-05-01" @default.
• W4220783418 modified "2023-10-18" @default.
• W4220783418 title "Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy" @default.
• W4220783418 cites W162361392 @default.
• W4220783418 cites W1987736934 @default.
• W4220783418 cites W2005229135 @default.
• W4220783418 cites W2006838975 @default.
• W4220783418 cites W2041060696 @default.
• W4220783418 cites W2051978340 @default.
• W4220783418 cites W2068967760 @default.
• W4220783418 cites W2088622502 @default.
• W4220783418 cites W2097618980 @default.
• W4220783418 cites W2118891131 @default.
• W4220783418 cites W2124624517 @default.
• W4220783418 cites W2147157981 @default.
• W4220783418 cites W2229279613 @default.
• W4220783418 cites W2291022027 @default.
• W4220783418 cites W2344755025 @default.
• W4220783418 cites W2583593970 @default.
• W4220783418 cites W2614809093 @default.
• W4220783418 cites W2736348067 @default.
• W4220783418 cites W2745956749 @default.
• W4220783418 cites W2754070252 @default.
• W4220783418 cites W2885213946 @default.
• W4220783418 cites W2895550784 @default.
• W4220783418 cites W2911119055 @default.
• W4220783418 cites W2957619611 @default.
• W4220783418 cites W2988396240 @default.
• W4220783418 cites W2990637825 @default.
• W4220783418 cites W3080292240 @default.
• W4220783418 cites W3101721924 @default.
• W4220783418 cites W3104775553 @default.
• W4220783418 cites W3109863995 @default.
• W4220783418 cites W3113392623 @default.
• W4220783418 cites W3136433515 @default.
• W4220783418 cites W3177059131 @default.
• W4220783418 cites W3202129080 @default.
• W4220783418 cites W3211575326 @default.
• W4220783418 cites W4206221685 @default.
• W4220783418 cites W4211100568 @default.
• W4220783418 cites W4212868194 @default.
• W4220783418 cites W4213172209 @default.
• W4220783418 cites W4250353787 @default.
• W4220783418 cites W4292528167 @default.
• W4220783418 cites W75744916 @default.
• W4220783418 doi "https://doi.org/10.1001/jamacardio.2022.0259" @default.
• W4220783418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35353129" @default.
• W4220783418 hasPublicationYear "2022" @default.
• W4220783418 type Work @default.
• W4220783418 citedByCount "19" @default.
• W4220783418 countsByYear W42207834182022 @default.
• W4220783418 countsByYear W42207834182023 @default.
• W4220783418 crossrefType "journal-article" @default.
• W4220783418 hasAuthorship W4220783418A5004676848 @default.
• W4220783418 hasAuthorship W4220783418A5008894558 @default.
• W4220783418 hasAuthorship W4220783418A5012618486 @default.
• W4220783418 hasAuthorship W4220783418A5012677271 @default.
• W4220783418 hasAuthorship W4220783418A5037677450 @default.
• W4220783418 hasAuthorship W4220783418A5038860730 @default.
• W4220783418 hasAuthorship W4220783418A5039494205 @default.
• W4220783418 hasAuthorship W4220783418A5041084808 @default.
• W4220783418 hasAuthorship W4220783418A5048283490 @default.
• W4220783418 hasAuthorship W4220783418A5050549187 @default.
• W4220783418 hasAuthorship W4220783418A5055613208 @default.
• W4220783418 hasAuthorship W4220783418A5064940993 @default.
• W4220783418 hasAuthorship W4220783418A5066469597 @default.
• W4220783418 hasAuthorship W4220783418A5067001113 @default.
• W4220783418 hasAuthorship W4220783418A5068745615 @default.
• W4220783418 hasAuthorship W4220783418A5071672663 @default.
• W4220783418 hasAuthorship W4220783418A5071798264 @default.
• W4220783418 hasAuthorship W4220783418A5077679832 @default.
• W4220783418 hasAuthorship W4220783418A5082764262 @default.
• W4220783418 hasAuthorship W4220783418A5083045371 @default.
• W4220783418 hasAuthorship W4220783418A5083665930 @default.
• W4220783418 hasBestOaLocation W42207834181 @default.

• next